Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Public ClinicalTrials.gov record NCT06463665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.
Study identification
- NCT ID
- NCT06463665
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 142 participants
Conditions and interventions
Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
Interventions
- Olvimulogene nanivacirepvec Biological
- Platinum chemotherapy: carboplatin or cisplatin Drug
- Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC Drug
- Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab Drug
- Docetaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2024
- Primary completion
- Jan 31, 2027
- Completion
- Jun 30, 2029
- Last update posted
- Jun 3, 2026
2024 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pioneer Research Center, LLC | Bullhead City | Arizona | 86442 | Recruiting |
| Clermont Oncology Center | Clermont | Florida | 34711 | Recruiting |
| Oncology & Hematology Associates of West Broward | Coral Springs | Florida | 33065 | Recruiting |
| Helios Clinical Research | Fort Lauderdale | Florida | 33316 | Recruiting |
| Bioresearch Partner | Hialeah | Florida | 33013 | Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| Bioresearch Partner | Miami | Florida | 33155 | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | Recruiting |
| BRCR Medical Center, Inc. | Plantation | Florida | 33322 | Recruiting |
| Michigan Hematology and Oncology Consultants | Dearborn | Michigan | 48126 | Recruiting |
| Oakland Medical Group | Farmington Hills | Michigan | 48336 | Recruiting |
| Inspira Medical Center Mullica Hill | Mullica Hill | New Jersey | 08062 | Recruiting |
| Gabrail Cancer and Research Center | Canton | Ohio | 44718 | Recruiting |
| Texas Oncology - Austin Central | Austin | Texas | 78745 | Recruiting |
| World Research Link | Baytown | Texas | 77521 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06463665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06463665 live on ClinicalTrials.gov.